|Bid||1.61 x 2000|
|Ask||2.55 x 600|
|Day's Range||2.43 - 2.50|
|52 Week Range||1.05 - 2.54|
|PE Ratio (TTM)||-2.23|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||4.38|
Verastem, Inc. , focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced an abstract featuring long-term follow up data from the DYNAMO® study evaluating duvelisib in patients with follicular lymphoma has been selected for oral presentation at the 22nd Congress of the European Hematology Association being held June 22-25, 2017 in Madrid, ...
NEW YORK, NY / ACCESSWIRE / May 11, 2017 / U.S. markets were relatively quiet Wednesday as investors analyzed the latest batch of corporate earnings. Additionally, President Trump on Wednesday announced ...
The Needham, Massachusetts-based company said it had a loss of 35 cents per share. Losses, adjusted for stock option expense, came to 32 cents per share. The results surpassed Wall Street expectations. ...